Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mihaela Munteanu

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Journal of Pediatric Hematology/Oncology|September 28, 2013
Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerabilityChris Fraser, Patrick Brown, Gail Megason, et al.
Investigational New Drugs|June 22, 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, et al.
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 studyTakaaki Tokito, Oleksii Kolesnik, Jens Sørensen, et al.
Investigational New Drugs|May 26, 2016
Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumorsCynthia M Nijenhuis, Edward Hellriegel, Jos H Beijnen, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyByoung Chul Cho, Irene Braña, Beatriz Cirauqui, et al.
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 studyIrfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaJohn M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Blood|March 5, 2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyIan W Flinn, Richard van der Jagt, Brad S Kahl, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Journal of Pediatric Hematology/Oncology|September 28, 2013
Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerabilityChris Fraser, Patrick Brown, Gail Megason, et al.
Investigational New Drugs|June 22, 2020
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, et al.
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 studyTakaaki Tokito, Oleksii Kolesnik, Jens Sørensen, et al.
Investigational New Drugs|May 26, 2016
Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumorsCynthia M Nijenhuis, Edward Hellriegel, Jos H Beijnen, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyByoung Chul Cho, Irene Braña, Beatriz Cirauqui, et al.
BMC Cancer|July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 studyIrfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaJohn M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
Blood|March 5, 2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyIan W Flinn, Richard van der Jagt, Brad S Kahl, et al.
Pageof 5